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doi:10.101Recombinant Human Granulocyte Colony-Stimulating
Factor Significantly Decreases the Expression of CXCR3
and CCR6 on T Cells and Preferentially Induces T helper
Cells to a T helper 17 Phenotype in Peripheral Blood
Harvests
Li-Xia Sun, Han-Yun Ren, Yong-Jin Shi, Li-Hong Wang, Zhi-Xiang QiuThe aim of this study was to investigate the expression of chemokine receptors on T cells and functional
changes of T helper (Th) cells in peripheral blood stem cell (PBSC) harvests after treating healthy donors
with recombinant human granulocyte colony-stimulating factor (rhG-CSF). Using multiparameter flow cy-
tometry, we analyzed the expression of CXCR3 and CCR6 on T cells and the production of interferon-g
(IFN-g), interleukin-4 (IL-4), and IL-17 by CD41 Th cells in PBSC grafts of healthy donors after in vivo
rhG-CSF application. Alterations in the relative expression levels of T cell receptor beta variable (TCRBV)
family members were determined using real-time polymerase chain reaction (PCR). rhG-CSF mobilization
significantly decreased the expression of CXCR3 and CCR6 on T cells. Treating donors with rhG-CSF re-
sulted in decreased IFN-g production and dramatically increased IL-4 and IL-17 secretion by CD41 Th cells,
leading to T cell polarization from the Th1 to the Th2 phenotype and a preferential increase in IL-17–pro-
ducing CD41 Th cells. We did not observe any differences in the relative expression levels of TCRBV family
members before and after in vivo rhG-CSF application. Our results suggest that the expression of CXCR3
and CCR6 on donor T cells was dramatically downregulated and an IL-17 phenotype of CD41 Th cells was
preferentially induced in PBSC grafts after treating healthy donors with rhG-CSF. The observed effects of
rhG-CSF on T cells may be independent of the relative expression levels of TCRBV family members.
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TCRBVINTRODUCTION
Currently, recombinant human granulocyte
colony-stimulating factor (rhG-CSF) mobilized pe-
ripheral blood stem cell (PBSC) grafts are a convenient
source of hematopoietic stem cells (HSCs) and have re-
placed marrow for autologous and most allogeneic
transplantations [1,2]. Neither the incidence nor the
severity of acute graft-versus-host disease (aGVHD)
is higher than with marrow transplantations, althoughepartment of Hematology, Peking University First Hos-
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6/j.bbmt.2009.03.016rhG-CSF-mobilized PBSC harvests contain many
more mature T cells [3,4]. This might be because of
the immunoregulatory effects of rhG-CSF on adaptive
immunity, such as the ability to switch the T cell
cytokine secretion profile to T helper (Th)2 responses
and the promotion of regulatory T cell and tolerogenic
dendritic cell differentiation [5–9]. However, these
mechanisms are not fully understood.
Previous studies showed that aGVHD necessitates
the migration of donor T cells to secondary lymphoid
organs independently of allogeneic disparity, where-
upon allospecific T cells can respond to host alloanti-
gens and then traffic to the target organs [10–14].
Chemokines are a family of structurally related che-
motactic proteins. Their interactions with chemokine
receptors are involved in many fundamental aspects
of immunology, including immune system develop-
ment, homeostasis, host inflammatory response, and
GVHD [15–17]. Chemokine receptors have been
instrumental in the characterization of subsets of
human T cells; CXCR3, CXCR6, and CCR5 are835
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CCR8 are expressed in Th2 cells. Data reported by
Anderson et al. and other researchers [18–22] suggest
that chemokine receptors, including CXCR3, CCR6,
CCR10, CCR2, and CCR5, expressed on donor T
cells may be crucial for lymphocyte migration and
homing to secondary lymphocyte tissues and target or-
gans during the onset of aGVHD. The important role
that CXCR3 and CCR6 play in the onset of aGVHD
was confirmed by the finding that blockade of
CXCR3 and deletion of the CCR6 gene could alleviate
the incidence and severity of aGVHD in human and
animal experiments [17,23,24].
Recent studies have investigated the effects ofTh17
cells on the development of GVHD [25]. Th17 cells,
a newly identified Th cell subset, produce high levels
of interleukin (IL)-17A (IL-17), IL-17F, IL-21, and
IL-22, and have been shown to contribute to mucosal
immunity [26]. Moreover, Th17 cells have been impli-
cated in allograft rejections of solid organs and several
autoimmune diseases [27–30]. Data from Yi et al. [31]
demonstrate that donor Th17 cells can downregulate
Th1 differentiation and ameliorate aGVHD after allo-
geneic hematopoietic stem cell transplantation
(HSCT). Acosta-Rodriguez et al. [32] provided a func-
tional link between CCR6 and IL-17, which have been
independently associated with tissue pathology. CCR6
has been shown to be involved in the recruitment of
pathogenic T cells in rheumatoid arthritis [33], exper-
imental autoimmune encephalitis [34], allergic pulmo-
nary inflammation, and psoriasis [15], and Th17 cells
are increasingly recognized as essential mediators of
those diseases [15,35]. Furthermore, an association be-
tween T cell receptors (TCR) and T cell anergy has
been identified [36]. At present, the effects of rhG-
CSF on the expression of chemokine receptors, secre-
tion of IL-17 cytokine by CD41 Th cells, and relative
expression levels of TCRBV family have not yet been
analyzed in detail. Therefore, in this study, we investi-
gated the expression profiles of CXCR3 and CCR6 on
T cells, the alteration of IL-17 production by Th cells,
and the relative expression levels of TCRBV family
members in rhG-CSF-mobilized PBSC harvests.MATERIALS AND METHODS
Sample Collection
Steady-state peripheral blood (SS-PB) samples
were collected from 15 individual healthy donors (8
males and 7 females, mean age: 31.4 6 11.8 years,
range: 14-53 years). Donors received rhG-CSF 5 mg/
kg subcutaneously once daily for 5 to 6 consecutive
days. rhG-CSF-mobilized PBSC grafts were collected
via apheresis for allogeneic PBSC transplantation. All
sample collections had the approval of the PekingUni-
versity First Hospital Ethical Committee. All graftsamples were washed twice with Iscove’s Modified
Dulbecco’s Medium (IMDM) and adjusted to a final
concentration of 5-10  106/mL for use. All samples
were processed within 6 hours of collection.
Flow-Cytometric Analysis of Cell Surface
Markers
Cells were stained without further separation to
minimize selective loss. Monoclonal antibodies (mAbs)
used for analyzing surface markers including CD3,
CD4, CD8, CXCR3 CCR6, IgG1, and IgG2a, were
conjugated with the fluorochromes phycoerythrin-
Texas Red-X (ECD), phycoerythrincyanin 5.1 (PC5),
peridin chlorophyll protein (PerCP), fluorescein iso-
thiocyanate (FITC), phycoerythrin (PE), and allophyco-
cyanin (APC). mAbs were purchased from Becton
Dickinson (Fullerton, CA) and Beckman Coulter (Full-
erton,CA).Onehundredmicroliters ofwholeperipheral
blood and diluted grafts were incubated with directly
conjugated antibodies specific to CD3, CD4, CD8,
CXCR3, CCR6, and isotype controls for 20 minutes
(concentrations according to manufacturers’ instruc-
tions). Red blood cells were then lysed in fluorescein-
activated cell sorter (FACS) solution. After washing in
phosphate-buffered saline (PBS) containing 1% bovine
serum albumin (BSA) and 0.1% sodium azide (NaN3),
cells were resuspended in PBS for analysis. A minimum
of 5000 lymphocyte-gated events were acquired and an-
alyzed with multiparameter flow cytometry (Coulter
Epics XL).
Intracellular Cytokine Staining Analysis
Whole PBSC and diluted grafts were stimulated by
phorbol-12-myristate-13-acetate (PMA) (50 ng/mL;
Sigma, St. Louis, MO) and ionomycin (1 mg/mL;
Sigma) in the presence of monensin (Golgistop 3
mM/mL; Sigma) for 4 hours at 37C in a 5% CO2 in-
cubator. Erythrocytes were then lysed and the cells
were labeled with anti-CD3 and anti-CD8 mAbs. Af-
terward, the cells were fixed and permeabilized with
FACS Permeabilizing Solution (Becton-Dickinson)
and stained with anti-IFNg-FITC, anti-IL-4-PE,
and anti-IL-17-APC mAbs (Becton Dickinson). As
a control, cells were stained with isotype mAbs. Cells
were then acquired and analyzed with BD FACSDiva
software (Becton-Dickinson).
Quantitative Real-Time PCR
Peripheral blood mononuclear cells (PBMCs)
were obtained using density gradient centrifugation
with Ficoll-Hypaque (density, 1.077 g/mL). Total
RNA was isolated from 1.5-5.0  106 PBMCs using
TRIzol Reagent according to the manufacturer’s di-
rections (Invitrogen, Carslbad, CA). cDNA was syn-
thesized using M-MLV reverse transcription,
random hexamer primers, and 10 mM dNTP
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veloped using the T cell receptor beta variable region
(TCRBV) classification system described by the Inter-
national ImMunoGeneTics database (LeFranc, 2008;
http://imgt.cines.fr/IMGT_GENE-DB). Primer and
probe design was performed using Primer Express
software version 3.0.
The relative expression of TCRBV family mem-
bers was determined using real-time PCR as previous
described [37], with somemodifications. Briefly, all ex-
periments were performed on an ABI 7300 sequence
detection system. Final reaction conditions involved
the amplification of 1 mL of cDNA in a 25-mL reaction
consisting of 10 PCR buffer containing 2.0 mM
magnesium chloride, 2.5 mM dNTPs, BC, and BV
primers, Taq DNA polymerase, a 5-mM dual-labeled
fluorescein probe, and Rox. Reactions were brought
up to final volume with sterile water. The relative ex-
pression levels of individual TCRBV transcripts were
then calculated as previously described [37,38].
Statistical Analysis
All of the normal distribution data were summa-
rized as the mean6 standard deviation (SD). Compar-
isons were performed using paired-sample t-tests. A
value of P\ .05 was considered statistically significant
for 2-sided tests. All analyses were performed with
SPSS software (version 11.5).RESULTS
Alteration of T Cell Subsets before and after
rhG-CSF Mobilization
Not only the total nucleated cells (TNC), but also
the percentage of lymphocytes, CD41, and CD81 T
cells within TNC were dramatically increased in
PBSC harvests after rhG-CSF mobilization (data not
shown). The percentage of CD31 T cells was higher
in PBSC grafts after rhG-CSF mobilization than in
SS-PB (42.93% 6 12.08% versus 25.266 5.00%; P\
.001). The percentages of CD31CD41 T cells and
CD31CD81Tcells did not differ significantly between
PBSC grafts and SS-PB (67.48% 6 7.04% versus
70.71%6 5.41%,P5 .087 and32.52%6 7.06%versus
29.21%6 5.45%,P5 .080; respectively). Furthermore,
the ratio of CD41 to CD81 cells was also unchanged
(2.22%6 0.74% versus 2.53%6 0.61%, P5 .099).
Downregulation of CXCR3 and CCR6
Expression in T Cell Subsets after In Vivo rhG-
CSF Application
To investigate the changes in chemokine receptor
phenotypes on T cells after rhG-CSF mobilization, we
analyzed the expressionofCXCR3andCCR6onTcells
before and after treating healthy donors with rhG-CSF.Figure1Ashowsa representativeexampleofCXCR3ex-
pression on T cells. Compared with SS-PB, the expres-
sion ofCXCR3 onCD31Tcells was significantly lower
in PBSC grafts (12.26% 6 6.58% versus 38.27% 6
4.63%, P \ .001). The expression of CXCR3 on
CD41 (6.04% 6 4.80% versus 29.34% 6 4.86%, P\
.001) and CD81 T cells (24.13% 6 10.88% versus
61.76%6 9.62%, P\ .001) was significantly decreased
after rhG-CSF mobilization (Figure 1B).
Figure 2A shows a representative example of
CCR6 expression on T cells. Compared with SS-PB,
expression of CCR6 on CD31T cells was significantly
decreased after in vivo rhG-CSF application (4.07%6
1.67% versus 14.46%6 3.50%, P\ .001). There were
significant differences between PBSC grafts and SS-
PB in the percentage of CCR6 expression on CD41
(3.16% 6 2.22% versus 15.12% 6 5.31%, P\ .001)
and CD81 T cells (6.53% 6 3.87% versus 12.57%
6 7.99%, P5 .007) (Figure 2B). Collectively, these ex-
periments show that T cells in PBSC grafts expressed
decreased amounts of CXCR3 and CCR6 markers.
Furthermore, these data indicate that CXCR3 and
CCR6 expression on T cell subsets is downregulated
after in vivo rhG-CSF application.rhG-CSFMobilization Polarizes TCells from the
Th1 to the Th2 Phenotype and Preferentially
Increases IL-17-Producing CD41 Th Cells
The proportion of IFN-g-, IL-4-, and IL-17-pro-
ducingCD41Tcells, both inSS-PB(n512)andPBSCs
(n 5 12), was determined using intracellular cytokine
staining. The results showed that 2.71% and 4.98% of
CD41 T cells from PBSC grafts produced IL-4 and
IL-17, respectively, upon activation, whereas only
0.83% and 0.85% of Th cells from PB produced these
2 cytokines, respectively (P\ .01). In contrast, the pro-
portion of IFN-g-producing CD41 T cells in PBSC
grafts was lower than in SS-PB samples (14.44% 6
7.36% versus 20.18%6 5.56%, P5 .017) (Figure 3A).
A representative example of IL-17–producing CD41 T
cells in PBSC grafts and SS-PB is shown in Figure 3B.
A representative example of IFN-g-producing and
IL-4-producing CD41 T cells is not shown.
We also calculated the ratios of IFN-g-, IL-4-, and
IL-17-producingCD41Tcells in PBSCgrafts and SS-
PB. As illustrated in Figure 4, the ratio of Th2:Th1 in
PBSC grafts was significantly higher than in SS-PB
(0.22 6 0.09 versus 0.04 6 0.01, P\ .01). Similarly,
the ratios of Th17:Th2 and Th17:Th1 in PBSC grafts
were, respectively, 2-fold and 8-fold higher than in SS-
PB (1.946 0.10 versus 1.026 0.40, P5 .013 and 0.35
6 0.12 versus 0.046 0.02, P\ .001). These data indi-
cate that polarization of T cells from the Th1 to the
Th2 phenotype could be induced and that IL-17-pro-
ducingCD41Th cells were preferentially increased af-
ter treating healthy donors with rhG-CSF.
Figure 1. CXCR3 expression on T cells in rhG-CSF-mobilized PBSC grafts (light symbols) and SS-PB (dark symbols). Mean values are represented by
horizontal lines in each series. (A) Representative example of CXCR3 expression on CD31, CD41, and CD81 T cells in SS-PB and PBSC grafts. (B)
Percentages of CXCR3 expression on CD31, CD41, and CD81 T cells before and after in vivo rhG-CSF application.
838 Biol Blood Marrow Transplant 15:835-843, 2009L.-X. Sun et al.No Alteration in Relative Expression of TCRBV
Family Members in PBSC Grafts after rhG-CSF
Administration
To investigate whether administering rhG-CSF to
mobilize stem cells causes skewing of the expressionlevels of genes in the TCRBV family, we determined
the relative expression levels of TCRBV family mem-
bers before and after rhG-CSF mobilization. Figure 5
shows that there were no significant differences in the
relative expression of TCRBV family members be-
tween PBSC grafts and SS-PB (P . .05).
Figure 2. CCR6 expression on T cells in rhG-CSF-mobilized PBSC grafts (light symbols) and SS-PB (dark symbols). Mean values are represented by
horizontal lines in each series. (A) Representative example of CCR6 expression on CD31, CD41, and CD81 T cells in SS-PB and PBSC grafts. (B) Per-
centages of CCR6 expression on CD31, CD41, and CD81 T cells before and after in vivo rhG-CSF application.
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In agreement with previous studies [7], we found
that the percentage ofCD31Tcells within nuclear cellsin rhG-CSF-mobilized PBSC grafts was higher than in
SS-PB, whereas the percentages of CD41 and CD81
T cell subsets, as well as the ratios of CD4:CD8 cells,
did not differ significantly before and after in vivo
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840 Biol Blood Marrow Transplant 15:835-843, 2009L.-X. Sun et al.rhG-CSF application. Our results and those of Tayebi
et al. [7] suggest that it was primarily the quality, not
the quantity, of T cells in PBSC harvests that changed
after in vivo rhG-CSF mobilization.
Rutella et al. [5] reported that they found no differ-
ences between freshly isolated pre-G-CSF and post-
G-CSF CD4 T cells in the expression of cell-surface
antigens including CXCR3 and CCR6, but they did0
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Figure 4. Ratios of IFN-g-, IL-4-, and IL-17-producing CD41 Th cells in
SS-PB (light bars) and rhG-CSF-mobilized PBSC grafts (dark bars).
*P\.01.not report in detail any changes in the expression of
these markers in nonisolated T cell harvests that were
transplanted to recipients. In the present study, we
found that treating healthy donors with rhG-CSF sig-
nificantly decreased the expression of CXCR3 and
CCR6 onT cells. Recently, using a well-defined exper-
imental bone marrow transplantation model (where
aGVHD is mediated by donor CD81T cells) to inves-
tigate the role of CXCR3 on donor cells in aGVHD,
Duffner et al. [39] found that CXCR3 is not required
for trafficking from venous circulation into secondary
lymphoid organs, but is needed for migration into ep-
ithelial target tissues. Moreover, blockading CXCR3
receptor/ligand interactions reduces leukocyte recruit-
ment to the lung and the severity of experimental idio-
pathic pneumonia syndrome [23]. Varona et al. [17]
demonstrated that CCR6 may cause T cells to migrate
directly to target tissues rather than through secondary
lymph nodes, which suggests that CCR6 plays a major
role in aGVHD development. Taken together, it is
conceivable that downregulation of CXCR3 and
CCR6 expression on donor CD41 and CD81 T cells
after in vivo rhG-CSF application may alter the migra-
tory ability of these T cells, as demonstrated by other
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Biol Blood Marrow Transplant 15:835-843, 2009 841Effects of rhG-CSF on Chemokine Receptor Expression and IL-17 Productionresearchers [17,23,39]. Also, chemokine receptor
CXCR3andCCR6expressionmay be affected byother
cytokines such IFN-g, IFN-a, and tumor growth fac-
tor (TGF)-b, present during Th cells polarization after
rhG-CSF application [40]. This could explain in part
the lack of amplification of aGVHD after transplanta-
tion, despite the presence of 10-fold more mature T
cells in rhG-CSF-mobilized PBSC harvests compared
with steady-state bone marrow grafts.
The polarization of T cells from the Th1 to the
Th2 phenotype has been observed by other researchers
[3,8,41-44]. Our results are in agreement with their ob-
servations, and show that rhG-CSF-mobilized PBSC
harvests contained significantly more IL-4-producing
cells (Th2) and less IFN-g-producing cells (Th1).
This suggests Th2 polarization, which might contrib-
ute to attenuation of aGVHD after rhG-CSF-mobi-
lized PBSC transplantation. To our minds, the most
important and interesting finding of our study was
that rhG-CSF mobilization preferentially induced
a Th17 phenotype, leading to higher ratios of IL-17-
producing cells (Th17) to IFN-g-producing cells
(Th1). This could contribute to the relative low
incidence of aGVHD in allogeneic PBSC transplant
settings, as demonstrated by Yi et al. [31] in mice
models. However, there have been conflicting studies
in which researchers found that IL-17 cannot prevent
the development of aGVHD and, indeed, may even ex-
acerbate it [45,46]. Therefore, the role of IL-17 in
aGVHD warrants further study, especially in clinical
settings. With regard to functional changes of CD41
Thcells [47], several possible explanationsmay account
for the increase in IL-4 and IL-17 production and the
decrease in IFN-g secretion that we observed. First,
rhG-CSF mobilization increased the secretion of IL-17, resulting in a decrease in IFN-g production by
CD41 Th cells as was previously observed in animal
models [31]; this led to the polarization of Th cells
from the Th1 to the Th2 phenotype. Second, rhG-
CSF application in vivo simultaneously increased the
production of IL-4 and IL-17, both of which suppress
the secretion of IFN-g. Third, rhG-CSF treatment
could directly increase IL-4 and IL-17 production
and decrease IFN-g secretion.
Recently, GATA-3 was identified as a T cell-spe-
cific transcription factor selectively expressed in Th2
cells [48]. Franzke et al. [41] found that GATA-3 could
be upregulated in CD41T cells upon rhG-CSF stimu-
lation, although GATA-3 directly represses the oppos-
ing Th1 immune response most likely by interfering
with the IL-12 signal transduction pathway. Therefore,
polarization of T cells fromTh1 toTh2 could be found
after in vivo rhG-CSF application. Furthermore, Th1
cells could negatively regulate the development of
Th2 and Th17 cells, so Th17 skewing was expected as
demonstrated in the current study [49].
In consideration of the evidence that CXCR3,
CXCR6, and CCR5 are ‘‘preferentially’’ expressed in
Th1 cells [32], our findings that rhG-CSF in vivo ap-
plication significantly decreased the percentage of
IFN-g-producing Th cells and that CXCR3 expres-
sion was significantly reduced suggest that not only
the function, but also the migratory characteristics,
of T cells were altered after treating healthy donors
with rhG-CSF. Another interesting finding of our
study was that there were no significant alterations in
the relative expression of TCRBV family members af-
ter treating healthy donors with rhG-CSF, suggesting
that rhG-CSF administration may not cause skewing
in the relative expression of TCRBV family members,
842 Biol Blood Marrow Transplant 15:835-843, 2009L.-X. Sun et al.although rhG-CSF has a direct and indirect immuno-
regulatory effect exerted by adaptive immunity. This
also suggests that a normal immune response could ex-
ist after treating healthy donors with rhG-CSF.
In conclusion, our results suggest that rhG-CSF
may have multiple effects on T cells, including the
downregulation of various chemokine receptors, thus
influencing the migratory ability of T cells to target or-
gans during aGVHD, and in the alteration of the Th1/
Th2/Th17 paradigm. The association between these
changes and transplant outcomes, especially with regard
to aGVHD, are currently being investigated in alloge-
neic transplant settings. This research may lead to
a more in-depth understanding of donor T cell migra-
tion andTh1/Th2/Th17 imbalance in rhG-CSF-mobi-
lized PBSC transplantation, and may contribute to an
effective strategy forGVHDprophylaxis and treatment.ACKNOWLEDGMENTS
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